UW-Madison researchers are celebrating a new executive order from President Donald Trump that expedites FDA approval for psychedelic treatments for conditions like depression and PTSD.
Paul Hutson from UW-Madison School of Pharmacy, who has studied psychedelics for mental health for years, says the new executive order will not only expedite FDA approvals but may help secure state funding for their research.